GlassScriptPhysician profile
Ignacio H Valdes
NPI 1760546360
$114,553.47
in general payments reported to CMS, 2019-2025
38 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,007 · 2020: $2,352 · 2021: $5,690 · 2022: $3,436 · 2023: $13K · 2024: $21K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Food and Beverage: $14K · Consulting Fee: $7,838 · Travel and Lodging: $1,338 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,060.75 |
| Food and Beverage | $13,777.57 |
| Consulting Fee | $7,837.50 |
| Travel and Lodging | $1,338.22 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50,646.40 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $26,439.09 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $19,476.97 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $2,453.76 | 2019-2025 | Aristada, Lybalvi |
| Noven Pharmaceuticals, INC. | $1,836.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $1,698.59 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,617.22 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,398.61 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,317.92 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $1,119.85 | 2019-2025 | Perseris, Sublocade |
| Corium, LLC | $905.43 | 2021-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $882.56 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $833.79 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $786.72 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $630.22 | 2021-2025 | Qelbree |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $515.38 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $301.39 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Axsome Therapeutics, INC. | $235.82 | 2024-2025 | Auvelity |
| Eisai INC. | $234.57 | 2020-2022 | |
| Noven Therapeutics, LLC | $224.14 | 2020-2025 | Xelstrym, Secuado |
| Shire North American Group INC | $215.84 | 2019 | |
| Allergan, INC. | $158.88 | 2019 | |
| Merck Sharp & Dohme LLC | $130.85 | 2022-2023 | Belsomra, Verquvo |
| Neos Therapeutics, LP | $66.54 | 2020-2021 | |
| Harmony Biosciences LLC | $57.01 | 2023-2024 | Wakix |
| Almatica Pharma LLC | $52.85 | 2025 | Loreev Xr |
| Mdd US Operations, LLC | $51.90 | 2020 | |
| Neuronetics, INC. | $50.78 | 2019-2023 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $47.77 | 2025 | Jornay Pm |
| Sun Pharmaceutical Industries INC. | $38.65 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $28.26 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $26.49 | 2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $24.00 | 2019 | |
| Luye Pharma (USA) LTD. | $18.84 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $15.23 | 2020 | |
| Acadia Pharmaceuticals INC | $15.15 | 2024 | Nuplazid |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.